Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. DOI:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25(35):5570–5577. DOI:10.1200/JCO.2007.12.5435
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez‐abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–Positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. DOI:10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1–Selected patients with NSCLC. N Engl J Med. 2020;383(14):1328–1339. DOI:10.1056/NEJMoa1917346
   PubMed Web of Science ®Google Scholar
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf
   Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. DOI:10.1056/NEJMoa1801005
   PubMed Web of Science ®Google Scholar
• Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer. J Clin Oncol. 2020;38(14):1505–1517. DOI:10.1200/JCO.19.03136
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. DOI:10.1056/NEJMoa1810865
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. DOI:10.1056/NEJMoa1716948
   PubMed Web of Science ®Google Scholar
• West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924–937. DOI:10.1016/S1470-2045(19)30167-6
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomized, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):S1470–2045. DOI:10.1016/S1470-2045(20)30641-0
   Web of Science ®Google Scholar
• Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 2019;135:188–195.
   PubMed Web of Science ®Google Scholar
• Spigel D, de Marinis F, Giaccone G, et al. Impower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC. LBA78. Ann Oncol. 2019;30:V915–V915.
   Web of Science ®Google Scholar
• Pallis AG, Papamichael D, Audisio R, et al. EORTC elderly task force experts’ opinion for the treatment of colon cancer in older patients. Cancer Treat Rev. 2010;36(1):83–90. DOI:10.1016/j.ctrv.2009.10.008
   PubMed Web of Science ®Google Scholar
• Santoro A, Bientinesi E, Monti D, et al. Immunosenescence and inflammaging in the aging process: age-related diseases or longevity? Ageing Res Rev. 2021;71:101422.
   PubMed Web of Science ®Google Scholar
• Ferrara R, Mezquita L, Auclin E, et al. Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter? Cancer Treat Rev. 2017;60:60–68.
   PubMed Web of Science ®Google Scholar
• Ferrara R, Naigeon M, Auclin E, et al. Circulating T-cell immunosenescence in patients with advanced non–small cell lung cancer treated with single-agent PD-1/PD-L1 inhibitors or platinum-based chemotherapy. Clin Cancer Res. 2021;2(2):492–503. DOI:10.1158/1078-0432.CCR-20-1420
   Google Scholar
• Pfirschke C, Engblom C, Rickelt S, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity. 2016;44(2):343–354. DOI:10.1016/j.immuni.2015.11.024
   PubMed Web of Science ®Google Scholar
• Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387–401. DOI:10.1016/S2213-2600(19)30084-0
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, Ramalingam SS, Ciuleanu T-E, et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial. J Thoracic Oncol. 2021;17(2):289–308. DOI:10.1016/j.jtho.2021.09.010
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). European public assessment report “Keytruda”. EMA Procedure No. EMA/H/C/003820/II/0043. (2023 May 8). https://ema.europa.eu/en/documents/variations-report/keytruda-h-c-3820-ii-043-epar-assessment-variation_en.pdf
   Google Scholar
• Velcheti V, Hu X, Chen X, et al. Clinical outcomes of pembrolizumab plus chemotherapy in non-squamous metastatic NSCLC patients aged 75 years or older at US oncology practices. Ann Oncol. 2020;31:S754–840.
   Google Scholar
• Paz-Ares L, Vicente D, Tafreshi A, et al. A randomized, placebo controlled trial of Pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol specified final analysis of KEYNOTE-407. J Thorac Oncol. 2020;15(10):1657–1669. DOI:10.1016/j.jtho.2020.06.015
   PubMed Web of Science ®Google Scholar
• Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized Phase III trial. J Thorac Oncol. 2020;15(8):1351–1360. DOI:10.1016/j.jtho.2020.03.028
   PubMed Web of Science ®Google Scholar
• Nishio M, Barlesi F, West H, et al. Atezolizumab Plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 impower132 trial. J Thorac Oncol. 2021;16(4):653–664. DOI:10.1016/j.jtho.2020.11.025
   PubMed Web of Science ®Google Scholar
• Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non–small-cell lung cancer. N Engl J Med. 2017;376(25):2415–2426. DOI:10.1056/NEJMoa1613493
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med. 2019;381(21):2020–2031. DOI:10.1056/NEJMoa1910231
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Ciuleanu TE, Pluzanski A, et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: three-year update from CheckMate 227 Part 1. Proc Am Soc Clin Oncol. 2020;38(15_suppl):9500. DOI:10.1200/JCO.2020.38.15_suppl.9500
   Google Scholar
• Johnson ML, Cho BC, Luft A, et al. PL02.01 durvalumab ± tremelimumab + chemotherapy as first-line treatment for mNSCLC: results from the Phase 3 POSEIDON study. J Thorac Oncol. 2021;16(10):S844. DOI:10.1016/j.jtho.2021.08.029
   Web of Science ®Google Scholar
• Rizvi N, Cho BC, Reinmuth N, et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer the MYSTIC Phase 3 randomized clinical trial. JAMA Oncol. 2020;6(5):661–674. DOI:10.1001/jamaoncol.2020.0237
   PubMed Web of Science ®Google Scholar
• Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: iFCT-0501 randomised, phase 3 trial. Lancet. 2011;378(9796):1079–1088. DOI:10.1016/S0140-6736(11)60780-0
   PubMed Web of Science ®Google Scholar
• Yan X, Wu Z, Han W, et al. Impact of age on the efficacy of immune checkpoint inhibitor-based combination therapy for non-small-cell lung cancer: a systematic review and meta-analysis. Front Oncol. 2020;10:1671.
   PubMed Web of Science ®Google Scholar
• Liu T, Ding S, Dang J, et al. First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wildtype epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis. J Thorac Dis. 2019;11(7):2899–2912. DOI:10.21037/jtd.2019.07.45
   PubMed Web of Science ®Google Scholar
• Morimoto K, Yamada T, Yokoi T, et al. Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. Lung Cancer. 2021;161:26–33.
   PubMed Web of Science ®Google Scholar